Compass Therapeutics, Inc. - CMPX STOCK NEWS

Compass Therapeutics reported progress in its clinical studies and financial results for Q3 2021. The company advanced CTX-009 to the second stage of a Phase 2a study, with a 29% overall response rate observed in 17 patients. CTX-471 demonstrated two partial responses in melanoma patients. The recent public offering raised $125 million, extending its cash runway into Q4 2024. R&D expenses decreased to $3.2 million, and general and administrative expenses dropped to $2.7 million. The net loss was $6 million, or $0.10 per share, an improvement from the previous year.

Compass Therapeutics, Inc. announced a public offering of 35,715,000 shares at $3.50 each, expected to raise approximately $125 million. The offering will close on November 4, 2021, and includes an option for underwriters to purchase an additional 5,357,250 shares. This follows the company's listing on the Nasdaq Capital Market under the symbol CMPX, effective November 2, 2021. Proceeds will fund ongoing clinical trials and operations. SVB Leerink is the book-running manager for the offering.

Compass Therapeutics, Inc. announces an underwritten public offering of shares of common stock, intending to secure its listing on the Nasdaq Capital Market under the symbol CMPX. The company expects to grant underwriters a 30-day option to purchase an additional 15% of the shares. Proceeds from the offering will fund clinical trials for ongoing operations and general corporate purposes. Offering details are based on a previously effective shelf registration statement. SVB Leerink is the book-running manager.

Compass Therapeutics (CMPX) announced progress on the Phase 2a study of CTX-009 for biliary tract cancers, initiated in Q1 2021 by Handok Pharmaceuticals. The study has met its criteria to advance, revealing a preliminary overall response rate of 29% with five partial responses from 17 patients. Additionally, 100% experienced stable disease or better. Compass plans to submit an Investigational New Drug (IND) application to the FDA this quarter, with a Phase 2 study anticipated in Q2 2022, aiming to enhance treatment options for cholangiocarcinoma.

Compass Therapeutics (OTC:CMPX) presented promising clinical data for CTX-009, a bispecific antibody targeting DLL4 and VEGF-A, at the AACR-NCI-EORTC conference. In a Phase 1 trial involving heavily pre-treated patients with colorectal and gastric cancers, CTX-009 showed an overall response rate (ORR) of 19% at recommended doses, with a disease control rate (DCR) of 69%. The drug was well tolerated, with no dose-limiting toxicities reported. Ongoing studies include a Phase 1b combination trial and a Phase 2 trial, enhancing its potential as a treatment for resistant solid tumors.

Compass Therapeutics, Inc. (OTC:CMPX) announced that data from its Phase 1 study of CTX-009, a bispecific antibody targeting DLL4 and VEGF-A, has been selected for oral presentation at the AACR-NCI-EORTC conference from October 7-10, 2021. The presentation will highlight safety, tolerability, and clinical activity data in patients with anti-VEGF-resistant solid tumors. CTX-009 has shown partial responses in heavily pre-treated patients and is currently advancing to Phase 1b and Phase 2 combination studies.

Compass Therapeutics, Inc. (OTC:CMPX), a clinical-stage biotechnology firm, announced that CEO Thomas Schuetz will participate in a fireside chat at the Citi 16th Annual Biopharma Conference on September 8, 2021, at 3:15 PM ET. The event will be accessible via the company’s website post-presentation. Compass Therapeutics focuses on developing proprietary antibody-based therapeutics targeting oncology, particularly through understanding angiogenesis and the immune system. Founded in 2014 and headquartered in Boston, the company aims to enhance anti-tumor responses through innovative therapies.

Compass Therapeutics (OTCQB: CMPX) has announced a definitive merger agreement with TRIGR Therapeutics, a private oncology firm. Compass will acquire TRIGR through a stock-for-stock transaction, approved unanimously by both companies' boards. At the center of the deal is CTX-009, a bispecific antibody that targets DLL4 and VEGF-A, currently in Phase 1b trials. The acquisition will enhance Compass' pipeline, and TRIGR's management will join Compass' board. Closing is anticipated in Q2 2021, with considerations including 10,265,154 shares issued to TRIGR shareholders.

Compass Therapeutics (CMPX) reported its 2020 financial results, highlighting a net loss of $29.5 million, a decrease from $34.7 million in 2019. The company successfully completed a $60.5 million private placement, enabling its transition to a public entity and OTCQB listing. Clinical progress includes the Phase 1b expansion of the CTX-471 study, showing promising anti-tumor activity, with data expected in the second half of 2021. Cash and cash equivalents stood at $47.1 million, providing operational runway until Q2 2022.